Table 1 Characteristics of Mothers with SARS-CoV-2 Infection
Characteristic | No. (%) |
|---|---|
Number of mothers | 67 |
Age, median (IQR), in years | 27 (21–31) |
Ethnicity | |
White | 6 (9%) |
Hispanic | 15 (22%) |
Black or African American | 44 (66%) |
Other | 2 (3%) |
Mode of delivery | |
Vaginal | 39 (58%) |
Cesarean | 28 (42%) |
Indications for Cesarean delivery | |
Repeat C-section. | 10 (36%) |
Worsening maternal condition due to COVID-19 | 3 (11%) |
Pre-eclampsia | 3 (11%) |
Chorioamnionitis | 2 (7%) |
Arrest of descent | 2 (7%) |
Malpresentation | 3 (11%) |
Fetal distress | 10 (36%) |
Severe IUGR | 2 (7%) |
Other | 5 (18%) |
Maternal condition before admission | |
Asymptomatic | 54 (81%) |
Sick at home | 9 (13%) |
Required hospitalization within 14 d prior to delivery | 4 (6%) |
Indication for SARS-CoV-2 testing | |
URI symptoms | 3 (5%) |
LRI symptoms | 8 (13%) |
Fever | 3 (5%) |
Gastrointestinal symptoms | 0 (0%) |
Myalgias or fatigue | 0 (0%) |
Anosmia or ageusia | 2 (2%) |
Contact with SARS-CoV-2 case | 3 (5%) |
Previous positive | 4 (6%) |
Asymptomatic screening | 55 (89%) |
SARS-CoV-2 status at time of delivery | |
Confirmed positive. | 42 (63%) |
Person under investigation (PUI) | 25 (37%) |
Time from diagnosis to delivery, median (IQR), in days | 1 (0–1.75) |
Specific treatment for SARS-CoV-2 | |
None | 61 (91%) |
Remdesivir | 3 (5%) |
Dexamethasone | 4 (4%) |
Convalescent plasma | 1 (2%) |
Length of stay, median (IQR), in days | 2 (2–3) |
Final maternal disposition | |
Discharged home | 67 (100%) |
Death | 0 (0%) |